Abstract
Intratumoral regulatory T-cells (Tregs) contribute to resistance to checkpoint inhibitors through various mechanisms (Saleh 2019). Intratumoral Tregs have a unique phenotype expressing higher levels of CD30 than other T-cells and non-tumor infiltrating Tregs in several malignancies including non-small cell lung cancer (NSCLC; De Simone 2016, Vasanthakumar 2017). BV (ADCETRIS®), a CD30-directed antibody-drug conjugate, has been shown to reduce Tregs in clinical trials of classical Hodgkin’s lymphoma and cutaneous T-cell lymphoma, to be uniquely toxic to CD30-expressing Tregs, and to allow for expansion of co-cultured CD8 T-cells in vitro (Romano 2019, Heister 2018 [AACR]).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call